A database of FDA approved therapeutic peptides and proteins
ID1142 | ThPPIDTh1020 | NameAsparaginase | Peptide SequenceQMSLQQELRYIEALSAIVET Full view | Length255 | Functional ClassificationIc | DiseaseCancer | BrandElspar | CompanyMerck & Co. Inc | Physical AppearanceLyophilized plug or powder | Route of AdministartionIntravenous or Intramuscular. Intravenous method dose has higher risk of allergic reaction, so often a test dose is given first. | CategoryAntineoplastic Agents | TargetL-asparagine |
ID1201 | ThPPIDTh1026 | NameAnistreplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIc | DiseaseHematological,Metabolic | BrandEminase | CompanyWulfing Pharma GmbH | Physical AppearanceDry powder | Route of AdministartionIntravenous infusion | CategoryThrombolytic Agents, Fibrinolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1260 | ThPPIDTh1037 | NameBotulinum Toxin Type B | Peptide SequenceMPVTINNFNYNDPIDNNNII Full view | Length255 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandMyobloc | CompanySolstice Neurosciences | Physical AppearanceClear and colorless to light-yellow sterile injectable solution | Route of AdministartionInjection | CategoryAntidystonic Agents | TargetVesicle-associated membrane protein 2,Vesicle-associated membrane protein 1,Synaptotagmin-2 |
ID1261 | ThPPIDTh1037 | NameBotulinum Toxin Type B | Peptide SequenceMPVTINNFNYNDPIDNNNII Full view | Length255 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandNeurobloc | CompanySolstice Neurosciences | Physical AppearanceClear and colourless to light yellow solution | Route of AdministartionIntramuscular Injection | CategoryAntidystonic Agents | TargetVesicle-associated membrane protein 2,Vesicle-associated membrane protein 1,Synaptotagmin-2 |
ID1288 | ThPPIDTh1042 | NameCollagenase | Peptide SequenceMKRKCLSKRLMLAITMATIF Full view | Length255 | Functional ClassificationIc | DiseaseHematological | BrandCordase | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryN.A. | TargetCollagen alpha-1(I) chain,Collagen alpha-1(II) chain,Collagen alpha-1(III) chain,Collagen alpha-2(I) chain |
ID1289 | ThPPIDTh1042 | NameCollagenase | Peptide SequenceMKRKCLSKRLMLAITMATIF Full view | Length255 | Functional ClassificationIc | DiseaseHematological | BrandSantyl | CompanyAdvance Biofactures Corp | Physical AppearanceSterile enzymatic debriding ointment | Route of AdministartionExternal use only | CategoryN.A. | TargetCollagen alpha-1(I) chain,Collagen alpha-1(II) chain,Collagen alpha-1(III) chain,Collagen alpha-2(I) chain |
ID1290 | ThPPIDTh1042 | NameCollagenase | Peptide SequenceMKRKCLSKRLMLAITMATIF Full view | Length255 | Functional ClassificationIc | DiseaseHematological | BrandXiaflex | CompanyAuxilium | Physical AppearanceSterile lyophilized powder (white cake) | Route of AdministartionIntralesional Injection | CategoryN.A. | TargetCollagen alpha-1(I) chain,Collagen alpha-1(II) chain,Collagen alpha-1(III) chain,Collagen alpha-2(I) chain |
ID1305 | ThPPIDTh1043 | NameRasburicase | Peptide SequenceSAVKAARYGKDNVRVYKVHK Full view | Length255 | Functional ClassificationIc | DiseaseMetabolic/Genetic | BrandElitek | CompanySanofi-Synthelabo Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous administration | CategoryAntihyperuricemic Agents, Gout suppressants | TargetUric acid |
ID1306 | ThPPIDTh1043 | NameRasburicase | Peptide SequenceSAVKAARYGKDNVRVYKVHK Full view | Length255 | Functional ClassificationIc | DiseaseMetabolic/Genetic | BrandFasturtec | CompanyN.A. | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionIntravenous administartion | CategoryAntihyperuricemic Agents, Gout suppressants | TargetUric acid |
ID1316 | ThPPIDTh1044 | NameAdalimumab | Peptide SequenceLight-chain:DIQMTQS< Full view | Length230 | Functional ClassificationIc | DiseaseImmunological | BrandHumira | CompanyAbbott Laboratories | Physical AppearanceSterile, preservative-free solution | Route of AdministartionSubcutaneous administration | CategoryImmunosuppressive Agents, Anti-inflammatory, Antirheumatic agents | TargetTumor necrosis factor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamm |
ID1317 | ThPPIDTh1044 | NameAdalimumab | Peptide SequenceLight-chain:DIQMTQS< Full view | Length230 | Functional ClassificationIc | DiseaseOsteological | BrandHumira Pen | CompanyAbbott Laboratories | Physical AppearanceSterile, preservative-free solution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents, Anti-inflammatory, Antirheumatic agents | TargetTumor necrosis factor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamm |
ID1337 | ThPPIDTh1048 | NamePegaspargase | Peptide SequenceMEFFKKTALAALVMGFSGAA Full view | Length255 | Functional ClassificationIc | DiseaseCancer | BrandOncaspar | CompanyEnzon Inc | Physical AppearanceSolution | Route of AdministartionIntravenous or Intramuscular administration | CategoryAntineoplastic Agents | TargetL-asparagine |
ID1381 | ThPPIDTh1059 | NameHyaluronidase | Peptide SequenceMWTGLGPAVTLALVLVVAWA Full view | Length476 | Functional ClassificationIc | DiseaseAdjunct Therapy | BrandHYLENEX | CompanyBaxter Healthcare Corporation | Physical AppearanceSterile, clear, colorless, nonpreserved, ready for use solution. | Route of AdministartionHuman Injection Subcutaneous use | CategoryAdjuvants, Anesthesia and Permeabilizing Agents | TargetN.A. |
ID1419 | ThPPIDTh1070 | NameBotulinum Toxin Type A | Peptide SequenceMPFVNKQFNYKDPVNGVDIA Full view | Length1296 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandBOTOX | CompanyAllergan | Physical AppearanceSterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strainClostridium botulinum type A | Route of AdministartionIntramuscular, intradetrusor and intradermal use | CategoryNeuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | TargetGrowth hormone receptor |
ID1420 | ThPPIDTh1070 | NameBotulinum Toxin Type A | Peptide SequenceMPFVNKQFNYKDPVNGVDIA Full view | Length1296 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandDysport | CompanyIpsen Pharmaceuticals | Physical AppearanceSterile vial for reconstitution | Route of AdministartionIntramuscular Injection | CategoryNeuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | TargetGrowth hormone receptor |
ID1421 | ThPPIDTh1070 | NameBotulinum Toxin Type A | Peptide SequenceMPFVNKQFNYKDPVNGVDIA Full view | Length1296 | Functional ClassificationIc | DiseaseNeurological Disorder | BrandXeomin | CompanyMERZ AESTHETICS | Physical AppearanceSterile white to off-white lyophilized powder after reconstitution with preservative-free 0.9% Saline for Injection. | Route of AdministartionIntramuscular Injection | CategoryNeuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | TargetGrowth hormone receptor |
ID1428 | ThPPIDTh1072 | NameStreptokinase | Peptide SequenceMKNYLSFGMFALLFALTFGT Full view | Length440 | Functional ClassificationIc | DiseaseMetabolic/Haemetological | BrandStreptase | CompanyCSL Behring | Physical AppearanceSterile, purified preparation formulated as lypholized powder | Route of AdministartionIntravenous and intracoronary administration. | CategoryFibrinolytic Agents and Thrombolytic Agents | TargetN.A. |
ID1477 | ThPPIDTh1097 | NameAlglucosidase Alfa | Peptide SequenceAHPGRPRAVPTQCDVPPNSR Full view | Length882 | Functional ClassificationIc | DiseaseMetabolic | BrandLUMIZYME | CompanyGenzyme | Physical AppearanceSterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with 10.3 Ml Sterile Water for Injection, USP | Route of AdministartionIntravenous infusion | CategoryEnzyme Replacement Agents | TargetCation-dependent mannose-6-phosphate receptor,Glycogen |
ID1621 | ThPPIDTh1134 | NameAsparaginase Erwinia Chrysanthemi | Peptide SequenceADKLPNIVILATGGTIAGSA Full view | Length327 | Functional ClassificationIc | DiseaseHormonal | BrandErwinaze | CompanyEUSA Pharma | Physical AppearanceSterile, lyophilized, white powder in vials. | Route of AdministartionIntramuscular injection | CategoryEnzymes | TargetN.A. |
ID1622 | ThPPIDTh1135 | NameOcriplasmin | Peptide SequenceTruncated heavy chai Full view | Length251 | Functional ClassificationIc | DiseaseEye Disorder | BrandJetrea | CompanyThromboGenics NV | Physical AppearanceSterile, clear and colorless solution with no preservatives | Route of AdministartionIntravitreal injection | CategoryOphthalmics | TargetFibronectin,Alpha-2-macroglobulin,Alpha-2-antiplasmin |
ID1623 | ThPPIDTh1136 | NameGlucarpidase | Peptide SequenceALAQKRDNVLFQAATDEQPA Full view | Length393 | Functional ClassificationIc | DiseaseHormonal | BrandVoraxaze | CompanyBTG International | Physical AppearanceSterile, preservative-free, white lyophilized powder in single-use vials | Route of AdministartionIntravenous injection | CategoryEnzymes | TargetMethotrexate |
ID1637 | ThPPIDTh1143 | NameFibrinolysin Aka Plasmin | Peptide SequenceFibrinolysin heavy c Full view | Length786 | Functional ClassificationIc | DiseaseHematological | BrandElase | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryN.A. | TargetN.A. |
ID1678 | ThPPIDTh1162 | NameAlirocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseMetabolic/Cardiac | BrandPraluent | CompanySanofi Aventis U.S. Llc | Physical AppearanceInjection, Solution | Route of AdministartionSubcutaneous | CategoryN.A. | TargetProprotein convertase subtilisin/kexin type 9 |
ID1679 | ThPPIDTh1162 | NameAlirocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseMetabolic/Cardiac | BrandPraluent | CompanySanofi Aventis Canada Inc | Physical AppearanceSolution | Route of AdministartionSubcutaneous | CategoryN.A. | TargetProprotein convertase subtilisin/kexin type 10 |
ID1680 | ThPPIDTh1162 | NameAlirocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseMetabolic/Cardiac | BrandPraluent | CompanySanofi Aventis Canada Inc | Physical AppearanceSolution | Route of AdministartionSubcutaneous | CategoryN.A. | TargetProprotein convertase subtilisin/kexin type 11 |
ID1681 | ThPPIDTh1162 | NameAlirocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseMetabolic/Cardiac | BrandPraluent | CompanySanofi Aventis U.S. Llc | Physical AppearanceInjection, Solution | Route of AdministartionSubcutaneous | CategoryN.A. | TargetProprotein convertase subtilisin/kexin type 14 |
ID1820 | ThPPIDTh1211 | NameIxekizumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseInfectious Disease | BrandTaltz | CompanyEli lilly | Physical AppearanceSterile, preservative free, clear and colorless to slightly yellow Solution | Route of AdministartionSubcutaneous | CategoryNA | TargetNA |